Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A universal antibody-derived targeting agent

R A Spooner1, M P Deonarain, P Savage

  • 1Royal Postgraduate Medical School, Department of Clinical Oncology, Hammersmith Hospital, London.

Cell Biophysics
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographics of epithelioid trophoblastic tumour and placental site trophoblastic tumour: a 21 year UK population study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2025
Same author

Dopamine-scrolling: a modern public health challenge requiring urgent attention.

Perspectives in public health·2025
Same author

Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020.

Prostate cancer and prostatic diseases·2021
Same author

Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.

ESMO open·2021
Same author

Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Arthroplasty infection rates in fractured neck of femur: single vs dual antibiotic cement.

Annals of the Royal College of Surgeons of England·2019
Same journal

Engineering recombinant antibodies for immunotherapy.

Cell biophysics·1995
Same journal

Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.

Cell biophysics·1995
Same journal

Animal models of human-derived cancer vaccines.

Cell biophysics·1995
Same journal

Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies.

Cell biophysics·1995
Same journal

Expression of nm23-H1 gene product in thyroid, ovary, and breast cancers.

Cell biophysics·1995
Same journal

Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines.

Cell biophysics·1995
See all related articles

Researchers developed a universal single-chain antibody fragment (ScFv) for targeted delivery. This antibody binds haptens, enabling drug or toxin delivery to specific cells via a two-step targeting strategy.

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Biology

Background:

  • Targeted drug delivery aims to enhance therapeutic efficacy and minimize side effects.
  • Current methods often lack universality and require specific targeting moieties for each cell type.

Purpose of the Study:

  • To develop a universal single-chain antibody fragment (ScFv) for targeted delivery to mammalian cells.
  • To establish a novel two-step targeting strategy for precise cellular delivery.

Main Methods:

  • Bacterial expression of a single-chain antibody fragment (ScFv) reactive against NP and NIP haptens.
  • Utilizing hapten-derivatized primary antibodies to capture the ScFv on target cells.

Main Results:

  • The ScFv demonstrated specific binding to NP and NIP haptens.

Related Experiment Videos

  • The two-step targeting strategy successfully enabled ScFv capture by hapten-derivatized antibodies on cells.
  • The ScFv did not bind to cells directly or to non-derivatized antibodies.

    • Conclusions:

    • The developed ScFv is a universal agent for targeted delivery of drugs, toxins, or radionuclides.
    • This strategy allows for cell-specific delivery using pre-existing antibodies.
    • The approach offers a versatile platform for various therapeutic applications.